Please login to the form below
Ionis Pharmaceuticals
This page shows the latest Ionis Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Ionis reports positive phase 2b results for fesomersen in thrombosis prevention
Ionis Pharmaceuticals has announced positive results from a phase 2b study of fesomersen, an investigational antisense medicine designed to reduce the production of Factor XI for the prevention of thrombosis, in ... The RE-THINC ESRD study was conducted
Latest news
-
Merck granted fast track designation by FDA for end-stage renal disease therapy
Bayer, for example, is trialling a factor XI antisense candidate – fesomersen – in collaboration with Ionis Pharmaceuticals in ESRD patients on haemodialysis.
-
Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy
Biogen has obtained a licence from Ionis Pharmaceuticals to develop and commercialise BIIB115/ION306, an investigational antisense oligonucleotide (ASO). ... Biogen and Ionis have a broad strategic collaboration to develop novel therapies to treat
-
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
AstraZeneca (AZ) has teamed up once more with California-based Ionis Pharmaceuticals, signing a global development and commercialisation agreement for its antisense therapy eplontersen. ... 2022. The AZ deal bolsters Ionis' commercial organisation as it
-
GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2
GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to
-
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
FDA surprises Akcea and Ionis with rejection of Waylivra. Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, has been knocked back by a surprise rejection via a Complete Response Letter (CRL) from ... However Ionis faces stiff competition from
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in ... Meanwhile, Karuna Pharmaceuticals has raised $42m to resurrect
-
Deal Watch October 2018
Tregs) while preserving effector T‐cells (Teffs). Acquisition. $759m. Ionis Pharmaceuticals/. Roche. ... US. US and Canada only. # US and EU. Roche’s collaboration with Ionis Pharmaceuticals has a headline of $760m, $1m more than the Tusk deal.
-
Deal Watch February 2017
Ionis Pharmaceuticals and Bayer entered into a licence in May 2015 for IONIS-FXIRx, an antisense therapeutic designed to reduce the production of Factor XI for the prevention of thrombosis. ... Licence, collaboration. 237.5. Portola Pharmaceuticals/
-
Deal Watch May 2016
This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
